Literature DB >> 21737516

The chemistry of thiosulfate and vascular calcification.

W Charles O'Neill1, Kenneth I Hardcastle.   

Abstract

BACKGROUND: Thiosulfate has been shown to inhibit vascular calcification in uremic rats and may inhibit calcification in humans with end-stage renal disease but whether this is due to a systemic or local action is unknown. The underlying mechanism is also unclear but complexation of calcium ions has been proposed.
METHODS: In vitro assays were used to determine the effect of thiosulfate on vascular calcification and hydroxyapatite formation.
RESULTS: Thiosulfate (EC50: 1-2 mM) prevented calcification of injured or devitalized aortas but not uninjured aortas, and similar results were obtained with sulfate. There was no effect on reversal of calcification. Measurements with an ion-sensitive electrode (corrected for changes in ionic strength) revealed a very weak interaction between thiosulfate and Ca(2+) (K(a) = 10.9 ± 1.0 × 10(-6) M(-1)) that resulted in a 4% decrease in ionized Ca(2+) in culture medium at 5 mM thiosulfate and a corresponding 5% increase in the solubility product for calcium-phosphate. Adjustment of the total Ca(2+) concentration to account for this did not prevent the inhibition of aortic calcification by thiosulfate. Thiosulfate did not inhibit hydroxyapatite formation from seed crystals or the calcification of purified elastin and did not alter medium pH.
CONCLUSIONS: Thiosulfate inhibits vascular calcification at millimolar concentrations through a direct extracellular effect that does not require intact smooth muscle cells but is related to cellular injury. This effect is not specific for thiosulfate since sulfate has similar properties. Inhibition cannot be explained by effects on ionized calcium, calcium-phosphate solubility, pH, oxidative stress or hydroxyapatite formation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21737516      PMCID: PMC3275785          DOI: 10.1093/ndt/gfr375

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  13 in total

Review 1.  Treatment of vascular calcification.

Authors:  W Charles O'Neill
Journal:  Kidney Int       Date:  2008-12       Impact factor: 10.612

2.  Inhibition of hydroxyapatite crystal growth by bone-specific and other calcium-binding proteins.

Authors:  R W Romberg; P G Werness; B L Riggs; K G Mann
Journal:  Biochemistry       Date:  1986-03-11       Impact factor: 3.162

3.  Studies on sulfate in end-stage renal disease.

Authors:  R M Freeman; C J Richards
Journal:  Kidney Int       Date:  1979-02       Impact factor: 10.612

4.  Successful sodium thiosulphate treatment for recurrent calcium urolithiasis.

Authors:  H Yatzidis
Journal:  Clin Nephrol       Date:  1985-02       Impact factor: 0.975

5.  Metabolic acidosis inhibits soft tissue calcification in uremic rats.

Authors:  F J Mendoza; I Lopez; A Montes de Oca; J Perez; M Rodriguez; E Aguilera-Tejero
Journal:  Kidney Int       Date:  2007-11-07       Impact factor: 10.612

6.  Sodium thiosulfate prevents vascular calcifications in uremic rats.

Authors:  Andreas Pasch; Thomas Schaffner; Uyen Huynh-Do; Brigitte M Frey; Felix J Frey; Stefan Farese
Journal:  Kidney Int       Date:  2008-09-24       Impact factor: 10.612

7.  Chemical and hormonal determinants of vascular calcification in vitro.

Authors:  K Lomashvili; P Garg; W C O'Neill
Journal:  Kidney Int       Date:  2006-04       Impact factor: 10.612

8.  Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure.

Authors:  Koba A Lomashvili; Marie-Claude Monier-Faugere; Xiaonan Wang; Hartmut H Malluche; W Charles O'Neill
Journal:  Kidney Int       Date:  2009-01-07       Impact factor: 10.612

9.  Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin.

Authors:  Koba A Lomashvili; Scott Cobbs; Randolph A Hennigar; Kenneth I Hardcastle; W Charles O'Neill
Journal:  J Am Soc Nephrol       Date:  2004-06       Impact factor: 10.121

10.  Thiosulfate reduces calcium phosphate nephrolithiasis.

Authors:  John R Asplin; Susan E Donahue; Christina Lindeman; Anne Michalenka; Kelly Laplante Strutz; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2009-04-15       Impact factor: 10.121

View more
  12 in total

1.  Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis.

Authors:  Joan Perelló; Miquel D Ferrer; Maria Del Mar Pérez; Nadine Kaesler; Vincent M Brandenburg; Geert J Behets; Patrick C D'Haese; Rekha Garg; Bernat Isern; Alex Gold; Myles Wolf; Carolina Salcedo
Journal:  Br J Pharmacol       Date:  2020-08-23       Impact factor: 8.739

2.  Zinc Inhibits Phosphate-Induced Vascular Calcification through TNFAIP3-Mediated Suppression of NF-κB.

Authors:  Jakob Voelkl; Rashad Tuffaha; Trang T D Luong; Daniel Zickler; Jaber Masyout; Martina Feger; Nicolas Verheyen; Florian Blaschke; Makoto Kuro-O; Andreas Tomaschitz; Stefan Pilz; Andreas Pasch; Kai-Uwe Eckardt; Juergen E Scherberich; Florian Lang; Burkert Pieske; Ioana Alesutan
Journal:  J Am Soc Nephrol       Date:  2018-04-13       Impact factor: 10.121

Review 3.  Calciphylaxis: risk factors, diagnosis, and treatment.

Authors:  Sagar U Nigwekar; Daniela Kroshinsky; Rosalynn M Nazarian; Jeremy Goverman; Rajeev Malhotra; Vicki Ann Jackson; Mihir M Kamdar; David J R Steele; Ravi I Thadhani
Journal:  Am J Kidney Dis       Date:  2015-05-07       Impact factor: 8.860

4.  Use of the optimized sodium thiosulfate regimen for the treatment of calciphylaxis in Chinese patients.

Authors:  Xin Yang; Yuqiu Liu; Xiaotong Xie; Wen Shi; Jiyi Si; Xiaomin Li; Xiaoliang Zhang; Bicheng Liu
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

5.  Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials.

Authors:  Chelsea Xu; Edward R Smith; Mark K Tiong; Irene Ruderman; Nigel D Toussaint
Journal:  J Am Soc Nephrol       Date:  2022-03-01       Impact factor: 14.978

6.  Sodium thiosulfate therapy for calcific uremic arteriolopathy.

Authors:  Sagar U Nigwekar; Steven M Brunelli; Debra Meade; Weiling Wang; Jeffrey Hymes; Eduardo Lacson
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-21       Impact factor: 8.237

7.  Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angiotensin II-induced hypertensive heart disease in rats.

Authors:  P M Snijder; A R Frenay; R A de Boer; A Pasch; J L Hillebrands; H G D Leuvenink; H van Goor
Journal:  Br J Pharmacol       Date:  2015-03       Impact factor: 8.739

8.  Can Sodium Thiosulfate Act as a Reversal Agent for Calcium Hydroxylapatite Filler? Results of a Preclinical Study.

Authors:  Wojciech Danysz; Bartosch Nowag; Thomas Hengl; Peter Kreymerman; Céline Furne; Elise Madeuf; Christoph Höennscheidt; Deanne Mraz Robinson
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-12-31

9.  Renal mitochondria can withstand hypoxic/ischemic injury secondary to renal failure in uremic rats pretreated with sodium thiosulfate.

Authors:  Dhivya Mohan; Eswari Dhivya Balasubramanian; Sriram Ravindran; Gino A Kurian
Journal:  Indian J Pharmacol       Date:  2017 Jul-Aug       Impact factor: 1.200

10.  Effect of mitochondrial potassium channel on the renal protection mediated by sodium thiosulfate against ethylene glycol induced nephrolithiasis in rat model.

Authors:  N Baldev; R Sriram; P C Prabu; A Kurian Gino
Journal:  Int Braz J Urol       Date:  2015 Nov-Dec       Impact factor: 1.541

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.